Current antiangiogenic immunotherapeutic strategies mainly focus on the blockade of circulating cytokines or receptors that are overexpressed by endothelial cells. We proposed globotriaosylceramide (Gb3) as a viable alternative target for antiangiogenic therapies. In this setting, we developed an anti-Gb3 antibody and validated its therapeutic efficacy in metastatic tumor models.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654593 | PMC |
| http://dx.doi.org/10.4161/onci.23700 | DOI Listing |
Publication Analysis
Top Keywords
inhibition tumor
4
tumor angiogenesis
4
angiogenesis globotriaosylceramide
4
globotriaosylceramide immunotargeting
4
immunotargeting current
4
current antiangiogenic
4
antiangiogenic immunotherapeutic
4
immunotherapeutic strategies
4
strategies focus
4
focus blockade
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!